Trial · NCT02261805
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
NCT02261805, Phase 1, Phase 2, Terminated, Georgetown University; results first posted 2018-02-07
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase I/II Study of Ganetespib in Combination With Doxorubicin. Trials, record NCT02261805. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02261805
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase I/II Study of Ganetespib in Combination With Doxorubicin
- NCT number
- NCT02261805
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- Georgetown University
- Conditions
- Cancer, Small Cell Lung Cancer
- Interventions
- Ganetespib, Doxorubicin
- First posted
- 2014-10-10
- Last updated
- 2018-04-23
- Results first posted
- 2018-02-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose | 1 year | The dose of ganetespib at which 1 or more out of 3-6 patients experiences a dose-limiting toxicity |
| Secondary | Objective Response Rate | 2 years | Objective response rate included the count of confirmed complete responses (CR) and partial responses (PR) and was based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Tolerated Dose | 1 year | mg/m^2 | NUMBER | |
| SECONDARY | Objective Response Rate | 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose | Ganetespib and Doxorubicin - Phase Ib Dose Level 1 | 100 | mg/m^2 | ||
| Maximum Tolerated Dose | Ganetespib and Doxorubicin - Phase Ib Dose Level 2 | 150 | mg/m^2 | ||
| Objective Response Rate | Ganetespib and Doxorubicin - Phase Ib Dose Level 1 | 1 | Participants | ||
| Objective Response Rate | Ganetespib and Doxorubicin - Phase Ib Dose Level 2 | 1 | Participants | ||
| Objective Response Rate | Ganetespib and Doxorubicin - Phase II Expansion | 0 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ganetespib and Doxorubicin - Phase Ib Dose Level 1 | 3 | |
| Overall Study | STARTED | Ganetespib and Doxorubicin - Phase Ib Dose Level 2 | 6 | |
| Overall Study | STARTED | Ganetespib and Doxorubicin - Phase II Expansion | 2 | |
| Overall Study | COMPLETED | Ganetespib and Doxorubicin - Phase Ib Dose Level 1 | 3 | |
| Overall Study | COMPLETED | Ganetespib and Doxorubicin - Phase Ib Dose Level 2 | 6 | |
| Overall Study | COMPLETED | Ganetespib and Doxorubicin - Phase II Expansion | 2 | |
| Overall Study | NOT COMPLETED | Ganetespib and Doxorubicin - Phase Ib Dose Level 1 | 0 | |
| Overall Study | NOT COMPLETED | Ganetespib and Doxorubicin - Phase Ib Dose Level 2 | 0 | |
| Overall Study | NOT COMPLETED | Ganetespib and Doxorubicin - Phase II Expansion | 0 |
Source ClinicalTrials.gov
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Ganetespib and Doxorubicin | 3 | 11 | 3 |
| other | Dysgeusia | Nervous system disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Fatigue | General disorders | Ganetespib and Doxorubicin | 6 | 11 | 7 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Alkaline phosphatase increased | Blood and lymphatic system disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Ganetespib and Doxorubicin | 3 | 11 | 4 |
| other | Depression | Psychiatric disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Ganetespib and Doxorubicin | 5 | 11 | 10 |
| other | Dyspepsia | Gastrointestinal disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ganetespib and Doxorubicin | 0 | 11 |
| Total, other adverse events | Ganetespib and Doxorubicin | 11 | 11 |
| Total, serious adverse events | Ganetespib and Doxorubicin | 1 | 11 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29594044 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02261805
GET https://conductscience.org/api/trials/v1/NCT02261805/events?page=2